By
MikeH on
October 2, 2012
Managing type 2 diabetes can be just as hard as managing type 1. Wouldn’t it be cool if someone were encouraging patients to set a motivational D-management goal for the week, and they’d donate $5 to an influential diabetes organization or charity in the process?
Well, that’s exactly what the ‘Mine’s own parent company Alliance Health Networks is doing right now at the huge DiabeticConnect community site. Alliance has been working with Edelman PR to develop a type 2 diabetes…
Read more »
You can walk away from diabetes-focused conferences with more than dry science and research news. Really, you can! That’s what I did recently after attending the Diabetes Today and Tomorrow conference held in the suburbs of Detroit on May 12. I took away two important nuggets of information that can help me better live with diabetes:
First, the key to achieving post-exercise stability in blood sugars may very well be in chocolate milk (!)
Secondly,…
Read more »
The biggest thing in diabetes headlines of late is Bydureon, the first and only once-a-week drug to help type 2 diabetics keep their sugars in check, which is newly approved by the FDA. Amylin’s stock price is up, and the pharma blogosphere is all abuzz. But if you’re like us, you may be wondering what the really big deal is. New type 2 drugs come out all the time, don’t they?
Well, for one thing,…
Read more »
Since we tend to be pretty America-centric over here, we wanted to shine a spotlight on the annual conference for the European Association for the Study of Diabetes (EASD), which is Europe’s equivalent to the American Diabetes Association. EASD is a huge professional org for doctors, researchers, nurses, students, and so on, with 7,000 members — from 110 different countries!
In addition to the annual conference, the EASD also produces their own trade publication, Diabetologia,…
Read more »
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »
